3.4 Specialized Topical & Transdermal Formulations

3.4 Specialized Topical & Transdermal Formulations

Specialized nonsterile dosage forms accommodate patient-specific clinical requirements that standard commercial products cannot fulfill. These include transdermal drug delivery gels (e.g., Pluronic Lecithin Organogel), sublingual/buccal troches, medicated sticks, hard candy lozenges, and veterinary-specific formulations. Mastering vehicle selection, chemical penetration enhancers, mechanical shearing techniques, and species-specific toxicities is essential for compounding technicians.

---

Topical vs. Transdermal Drug Delivery

• Topical Delivery: Formulations applied to intact skin to exert local therapeutic action within the epidermis or dermis (e.g., topical hydrocortisone for eczema, clindamycin gel for acne). Systemic absorption is unintended and minimized.
• Transdermal Delivery: Formulations designed to cross the primary cutaneous barrier—the Stratum Corneum—to deliver therapeutic drug concentrations into the dermal microvasculature for systemic effect (e.g., transdermal hormone replacement, ketoprofen PLO gel, feline methimazole pinna gel).

The Stratum Corneum Barrier & Penetration Enhancers

The stratum corneum consists of flattened, keratin-filled corneocytes surrounded by an intercellular lipid matrix ("brick-and-mortar model"). To facilitate drug transport across this hydrophobic barrier, compounders incorporate chemical penetration enhancers:

1. Lecithin: Phospholipid that fluidizes stratum corneum intercellular lipid bilayers.
2. Isopropyl Palmitate / Isopropyl Myristate: Fatty acid esters that enhance lipophilic drug solubility and lipid partition.
3. Dimethyl Sulfoxide (DMSO): Potent solvent that disrupts keratin structure and alters intercellular lipid arrangement.
4. Propylene Glycol & Oleic Acid: Synergistic penetration enhancers that increase drug diffusivity through dermal layers.

---

Pluronic Lecithin Organogel (PLO Gel) Architecture & Compounding

PLO gel is a microemulsion gel system widely utilized as a transdermal vehicle for lipophilic and hydrophilic active pharmaceutical ingredients.

Composition of PLO Gel

PLO gel comprises two distinct phases mixed in a specific ratio (typically 20–22% Organic Oil Phase and 78–80% Aqueous Pluronic Phase):

1. Organic Oil Phase (L.I.P. Phase): A 1:1 mixture of Soya Lecithin (granular) and Isopropyl Palmitate (or Isopropyl Myristate) liquid, plus Sorbic Acid (preservative). Lecithin acts as a surfactant and skin permeation enhancer; isopropyl palmitate serves as the lipophilic solvent.
2. Aqueous Phase (Pluronic F-127 Gel): A 20% to 30% w/v dispersion of Pluronic F-127 (Poloxamer 407) in chilled Purified Water, preserved with Potassium Sorbate.

Reverse Thermal Gelation of Pluronic F-127

Pluronic F-127 exhibits reverse thermal gelation:

• Refrigerated (2°C – 8°C): Polyoxyethylene-polyoxypropylene chains form strong hydrogen bonds with water molecules, keeping the liquid free-flowing.
• Room/Body Temp (20°C – 37°C): Hydrophobic interactions between polyoxypropylene blocks dominate, causing micellar aggregation into a solid, clear polymer gel matrix.

Dual-Syringe High-Shear Mixing Method

To compound a stable PLO gel, technicians employ high-shear mechanical mixing using two Luer-lock syringes connected via a Luer-to-Luer transfer adapter:

1. API Dissolution: Dissolve lipophilic APIs in the L.I.P. organic phase. Dissolve hydrophilic APIs in the chilled Pluronic aqueous phase.
2. Syringe Loading: Place the L.I.P. organic phase in Syringe A. Place the Pluronic aqueous phase in Syringe B.
3. Mechanical Shearing: Connect the syringes securely to the Luer-to-Luer adapter. Rapidly push the plungers back and forth 20 to 50 times, forcing the liquid mixture through the narrow orifice under high shear force.
4. Gel Formation: Mechanical shearing breaks the phases into fine micro-droplets, forming a smooth, creamy, opaque, yellow-white gel.

---

Troches, Lozenges, Sublingual Films, & Medicated Sticks

Transmucosal Delivery (Sublingual & Buccal)

Sublingual troches and buccal films dissolve against oral mucosa. The fraction absorbed through the mucosa can bypass gastrointestinal absorption and reduce first-pass metabolism; any swallowed fraction still follows the gastrointestinal and hepatic route.

Matrix Types & Compounding Characteristics

• PEG Troches (Soft Troches): Base consists of PEG 1450 and PEG 4000. Poured into plastic troche molds (typically 1.0 mL cavities) at 50–55°C. Dissolve smoothly in oral cavity.
• Hard Candy Lozenges: Sucrose, corn syrup, or polyols (Isomalt, Sorbitol). The mixture is heated to the hard-crack stage (149°C – 154°C / 300°F – 310°F) to drive off residual water (<2%). Heat-labile APIs are added after cooling the syrup slightly to 110–120°C prior to pouring into metal or silicone molds.
• Chewable Gummy Troches: Gelatin, glycerin, purified water, and intense sweeteners (sucralose, stevia). Poured into gummy molds.
• Medicated Sticks: Lip balms, styptic sticks, sunblocks. Formulated with high-melting-point waxes (Beeswax 62–65°C, Carnauba wax 82–86°C) combined with vegetable oils or cocoa butter. Poured into applicator tubes and cooled slowly to prevent central shrinkage cavity formation ("sinkholes").

---

Veterinary Specialized Compounding & Critical Excipient Toxicities

Veterinary compounding requires custom dosage forms tailored to animal species, body weight, and behavioral compliance. Common veterinary dosage forms include oral pastes in dial-a-dose syringes, flavored suspensions (tuna, beef, chicken, liver), otic gels, and transdermal pinna gels (applied to the inner hairless ear pinna of cats).

Critical Excipient Toxicities in Animals

Compounding technicians must possess rigorous knowledge of species-specific excipient toxicities. Excipients safe for humans can be fatal to domestic animals:

---

Worked Numerical Examples

Worked Example 1: Ketoprofen 10% PLO Gel Compounding Calculation

Scenario: Compound 60 g of Ketoprofen 10% PLO Gel for systemic transdermal pain management. The formula calls for 22% L.I.P. organic phase and 78% Pluronic F-127 20% gel phase. Ketoprofen API dissolves in the L.I.P. phase. Calculate the mass of Ketoprofen API, volume of L.I.P. phase, volume of Pluronic F-127 gel phase, and outline high-shear mixing.

Solution Steps:

1. Calculate Ketoprofen API mass required:

   • Target total weight = 60 g
   • API mass = 60 g * 0.10 = 6.00 g Ketoprofen API

2. Calculate vehicle remaining after the API:

   • Vehicle mass = 60.00 g final − 6.00 g API = 54.00 g vehicle

3. Split the 54.00 g vehicle into its phases:

   • L.I.P. phase = 54.00 g × 0.22 = 11.88 g
   • Pluronic F-127 gel phase = 54.00 g × 0.78 = 42.12 g
   • Check: 6.00 + 11.88 + 42.12 = 60.00 g final

4. Compounding Execution: Incorporate the 6.00 g ketoprofen into 11.88 g L.I.P. phase as the approved formulation directs. Place that phase and 42.12 g chilled Pluronic gel in separate compatible syringes, connect them, and pass the material between syringes until homogeneous. Package in the master-formulation-specified container.

---

Worked Example 2: Feline Methimazole Transdermal Pinna Gel Formulation

Scenario: Prepare 10 mL of Methimazole 5 mg/0.1 mL transdermal gel for a cat with hyperthyroidism. Calculate total API mass, select safe non-toxic excipients, and calculate individual dose delivery.

Solution Steps:

1. Calculate total Methimazole API mass:

   • Target concentration = 5 mg per 0.1 mL = 50 mg/mL
   • Total volume = 10 mL
   • Total API mass = 10 mL * 50 mg/mL = 500 mg Methimazole API

2. Excipient Safety Check for Feline Patient:

   • Check: Ensure vehicle contains NO Propylene Glycol (prevents Heinz body anemia) and NO Benzyl Alcohol.
   • Vehicle Choice: Use Lecithin/Isopropyl Palmitate (L.I.P.) oil phase and Pluronic F-127 aqueous gel phase preserved with potassium sorbate.

3. Dose Delivery Calculation:

   • Prescribed dose = 5 mg (0.1 mL) applied to inner ear pinna twice daily.
   • A 10 mL syringe provides 100 doses (10 mL / 0.1 mL per dose).